As a leading company with extensive expertise in in-vivo delivery of nucleic acids, Polyplus-transfection® is involved in a growing number of preclinical studies and clinical trials worldwide and in addition, the company is conducting its own exciting and innovative research programs in the field of in vivo delivery of siRNA.
Preclinical & Clinical ReagentsFor preclinical and clinical trials, Polyplus-transfection offers reagents supported by the appropriate manufacturing quality controls, full documentation and certification.
Polyplus Internal Research Programs
Effective delivery is recognized as being the major unsolved problem in nucleic acid-based therapeutic approaches.
Among these, RNA interference-based therapies and siRNA delivery are the latest challenges. Polyplus, as an expert in nucleic acid delivery, continuously develops new solutions for siRNA in vivo. Polyplus is rapidly developing its STICKY SIRNA™ technology for to provide dramatically improved carrier-mediated delivery)and in parallel also expanding its SIRNAPLUS™ molecular delivery solution in which no vector is required for high efficiency delivery.
Trials of several drug candidates using Polyplus reagents as nucleic acid delivery vectors are in progress worldwide.
Beside, Polyplus-transfection’s own R&D is developing discovery models for the SIRNAPLUS and STICKY SIRNA technologies.
Beside, Polyplus-transfection’s own R&D is developing discovery models for the SIRNAPLUS and STICKY SIRNA technologies.
